<SEC-DOCUMENT>0001193125-19-280582.txt : 20191031
<SEC-HEADER>0001193125-19-280582.hdr.sgml : 20191031
<ACCEPTANCE-DATETIME>20191031170513
ACCESSION NUMBER:		0001193125-19-280582
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20191031
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191031
DATE AS OF CHANGE:		20191031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		191184409

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d816951d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20191031" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2019-10-31_to_2019-10-31">AMGEN INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2019-10-31_to_2019-10-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2019-10-31_to_2019-10-31">0000318154</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20191031.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2019-10-31_to_2019-10-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-31</xbrli:startDate> <xbrli:endDate>2019-10-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-31</xbrli:startDate> <xbrli:endDate>2019-10-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-31</xbrli:startDate> <xbrli:endDate>2019-10-31</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-31</xbrli:startDate> <xbrli:endDate>2019-10-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Washington, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">Form <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2019-10-31_to_2019-10-31">8-K</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section 13 OR 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt:datemonthdayyearen">October 31, 2019</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:12pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amgen Inc.</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2019-10-31_to_2019-10-31">001-37702</ix:nonNumeric> </span></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2019-10-31_to_2019-10-31">95-3540776</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">of incorporation)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr>
<tr style="font-size:1pt;">
<td colspan="3" style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2019-10-31_to_2019-10-31">One Amgen Center Drive</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2019-10-31_to_2019-10-31">Thousand Oaks</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td>&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2019-10-31_to_2019-10-31">91320-1799</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td>&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Registrant&#8217;s telephone number, including area code</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2019-10-31_to_2019-10-31">(805)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2019-10-31_to_2019-10-31">447-1000</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table> <p style="font-family:Times New Roman;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol(s)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Global Select Market LLC</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">1.250% Senior Notes Due 2022</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">AMGN22</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR &#167;<span style="white-space:nowrap">240.12b-2). </span></p> <p style="font-family:Times New Roman;text-align:right;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2019-10-31_to_2019-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="font-family:Times New Roman;text-align:justify;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> <div></div> <p style="margin-top:0"></p></div>

<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;1.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Entry Into a Material Definitive Agreement</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On October&#160;31, 2019, Amgen Inc. (&#8220;<span style="text-decoration:underline">Amgen</span>&#8221;) entered into a Collaboration Agreement (the &#8220;<span style="text-decoration:underline">Collaboration Agreement</span>&#8221;) with BeiGene Switzerland GmbH (&#8220;<span style="text-decoration:underline">BeiGene Switzerland</span>&#8221;), a wholly-owned subsidiary of BeiGene, Ltd. (&#8220;<span style="text-decoration:underline">BeiGene</span>&#8221;), pursuant to which Amgen and BeiGene Switzerland will, either directly or acting through one or more of their affiliates, collaborate on the commercialization of Amgen&#8217;s oncology products XGEVA<sup style="font-size:85%;vertical-align:top">&#174;</sup> (denosumab), KYPROLIS<sup style="font-size:85%;vertical-align:top">&#174;</sup> (carfilzomib) and BLINCYTO<sup style="font-size:85%;vertical-align:top">&#174;</sup> (blinatumomab) in China (excluding Hong Kong, Macao and Taiwan, the &#8220;<span style="text-decoration:underline">Territory</span>&#8221;) and the global development and commercialization in the Territory of 20 Amgen clinical- and late-preclinical-stage oncology pipeline products. In connection with the Collaboration Agreement, BeiGene Switzerland will be required to commit up to $1.25&#160;billion towards global development cost sharing related to the oncology pipeline products. BeiGene has guaranteed certain obligations of BeiGene Switzerland under the Collaboration Agreement pursuant to the terms of a separate Guarantee Agreement. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Additionally, Amgen entered into a Share Purchase Agreement (the &#8220;<span style="text-decoration:underline">Share Purchase Agreement</span>&#8221;) with BeiGene pursuant to which BeiGene agreed to issue and sell, and Amgen agreed to purchase, in a private placement, an aggregate of approximately $2,734&#160;million of BeiGene&#8217;s ordinary shares, par value $0.0001 per share. This purchase implies a price of $174.85 per American Depositary Share (&#8220;<span style="text-decoration:underline">ADS</span>&#8221;), representing a 36% premium to BeiGene&#8217;s <span style="white-space:nowrap">30-day</span> volume-weighted average share price as of October&#160;30, 2019, and is expected to result in Amgen holding approximately 20.5% of BeiGene&#8217;s outstanding shares upon the closing of the share purchase under the Share Purchase Agreement (the &#8220;<span style="text-decoration:underline">Closing</span>&#8221;) upon which the Collaboration Agreement will become effective. As part of the Share Purchase Agreement, Amgen will receive the right to designate an independent director to serve on BeiGene&#8217;s board of directors. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Collaboration Agreement, Share Purchase Agreement and transactions contemplated thereunder have been approved by the boards of directors of both Amgen and BeiGene, and the Closing is expected in the first quarter of 2020, subject to approval by a majority vote of BeiGene&#8217;s shareholders pursuant to the listing rules of the Hong Kong Stock Exchange, the expiration or termination of applicable waiting periods under all applicable antitrust laws, and satisfaction of other customary closing conditions. Shareholders of BeiGene currently holding an aggregate of approximately 40% of the outstanding shares have agreed to vote in favor of the transactions. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Collaboration Agreement and Share Purchase Agreement are further summarized below. </p> <p style="font-family:Times New Roman;font-weight:Bold;font-style:Italic;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">Collaboration Agreement </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">Under the terms of the Collaboration Agreement, BeiGene Switzerland will be responsible for commercializing Amgen&#8217;s oncology products XGEVA<sup style="font-size:85%;vertical-align:top">&#174;</sup> (denosumab), KYPROLIS<sup style="font-size:85%;vertical-align:top">&#174;</sup> (carfilzomib) and BLINCYTO<sup style="font-size:85%;vertical-align:top">&#174;</sup> (blinatumomab) in the Territory following (i)&#160;the first commercial sale in the Territory for each of KYPROLIS<sup style="font-size:85%;vertical-align:top">&#174;</sup> and BLINCYTO<sup style="font-size:85%;vertical-align:top">&#174;</sup> and (ii)&#160;the transition of operational responsibilities for XGEVA<sup style="font-size:85%;vertical-align:top">&#174;</sup>. KYPROLIS<sup style="font-size:85%;vertical-align:top">&#174;</sup> and BLINCYTO<sup style="font-size:85%;vertical-align:top">&#174;</sup> are both in Phase 3 trials in China and XGEVA<sup style="font-size:85%;vertical-align:top">&#174;</sup> was launched in China in September of this year. Amgen and BeiGene Switzerland will each share half of the profits and losses in the Territory for these products during their respective commercialization periods, after which BeiGene Switzerland will have the right to retain commercial rights to one product following the commercialization period for as long as such product is sold in the Territory. Commercial rights for two of the products will be returned to Amgen: after five years for one and after seven years for the other. For each such product returned to Amgen, Amgen will pay royalties in the <span style="white-space:nowrap">low-double</span> digit percentages declining to <span style="white-space:nowrap">mid-single</span> digit percentages on any net sales of such product in the Territory generated by or on behalf of Amgen for an additional five years. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Additionally, under the terms of the Collaboration Agreement, Amgen and BeiGene Switzerland, either directly or acting through one or more of their affiliates, have agreed to collaborate on the development of 20 Amgen oncology pipeline products, with BeiGene Switzerland responsible for conducting development activities in or for the benefit of the Territory pursuant to a global development plan and budget controlled by Amgen (the &#8220;<span style="text-decoration:underline">Global Plan</span>&#8221;). Starting from the commencement of the Collaboration Agreement, Amgen and BeiGene Switzerland will share the global development costs for the oncology pipeline products pursuant to certain specified allocations, with BeiGene Switzerland contributing up to an aggregate of $1.25&#160;billion. BeiGene Switzerland will be credited for <span style="white-space:nowrap">in-kind</span> contributions of development activities conducted by it and/or its affiliates in or for the benefit of the Territory, as well as half of the cost savings that results from BeiGene Switzerland&#8217;s participation in development activities. Upon regulatory approval in the Territory of each oncology pipeline product, BeiGene Switzerland will be responsible for commercializing each such approved oncology pipeline product in the Territory for seven years, during which time Amgen and BeiGene Switzerland will each share half of the profits and losses for the product in the Territory. After the expiration of such commercialization period for each approved oncology pipeline product, the product will either be (i)&#160;returned to Amgen or (ii)&#160;retained by BeiGene Switzerland for as long as such product is sold in the Territory. BeiGene Switzerland will retain up to six oncology pipeline products based on how many of the 20 Amgen oncology pipeline products receive approval in the Territory, other than AMG 510, Amgen&#8217;s KRAS<sup style="font-size:85%;vertical-align:top">G12C</sup> inhibitor that is being studied as a potential treatment for advanced <span style="white-space:nowrap">non-small</span> cell lung and colorectal cancers. </p> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Amgen will pay royalties in the <span style="white-space:nowrap">mid-single</span> digit percentages on any net sales outside of the Territory of each approved oncology pipeline product (other than AMG 510), on a <span style="white-space:nowrap">product-by-product</span> and <span style="white-space:nowrap">country-by-country</span> basis, until the latest of (i)&#160;the expiration of the last valid patent claim owned or exclusively controlled by Amgen, (ii)&#160;the expiration of regulatory exclusivity, or (iii)&#160;the earlier of (x)&#160;eight years after the first commercial sale of such product in the country of sale or (y) 20 years after the first commercial sale of such product anywhere in the world. Additionally, after the return of each such oncology pipeline product to Amgen, Amgen will pay royalties in the <span style="white-space:nowrap">low-double</span> digit percentages declining to single-digit percentages on any net sales of such product in the Territory generated by or on behalf of Amgen for an additional five years. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Collaboration Agreement contains customary representations, warranties and covenants by the parties, and will continue in effect on a <span style="white-space:nowrap">product-by-product</span> basis unless terminated by either party pursuant to its terms. Amgen and BeiGene Switzerland will enter into transition services agreements for the transfers of product-related assets and capabilities to BeiGene Switzerland and the reversions to Amgen. Additionally, BeiGene has provided a guarantee with respect to BeiGene Switzerland&#8217;s obligations under the Collaboration Agreement. Either Amgen or BeiGene Switzerland may terminate the Collaboration Agreement in its entirety for the other side&#8217;s insolvency, uncured material breach, failure to comply with specified compliance provisions or subject to a specified negotiation mechanism, certain adverse legal or regulatory changes or failure to meet commercial objectives. In addition, either Amgen or BeiGene Switzerland may terminate the Collaboration Agreement with respect to a particular product in the event of an uncured material breach with respect to such product or a failure to meet commercial objectives for such product. Amgen may terminate the Collaboration Agreement with respect to a particular product if it has suspended development and commercialization activities for such product outside of the Territory, subject to further agreement between Amgen and BeiGene Switzerland regarding the development and commercialization of such product in the Territory. During the term of the Collaboration Agreement, Amgen and BeiGene Switzerland are subject to certain restrictions in the Territory and worldwide related to the clinical development, commercial manufacture, distribution and commercialization of certain products that, as a therapeutic mechanism of action, are directed to certain targets of the products in the collaboration. </p> <p style="font-family:Times New Roman;font-weight:Bold;font-style:Italic;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">Share Purchase Agreement </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">The offer and sale of the shares to be issued pursuant to the Share Purchase Agreement will be made in a private placement in reliance upon the exemption from registration provided by Section&#160;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act</span>&#8221;), for transactions by an issuer not involving a public offering, and/or Regulation D under the Securities Act. All certificates evidencing the shares will bear a standard restrictive legend under the Securities Act. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Amgen has agreed in certain specified circumstances to a standstill, which commenced on October&#160;31, 2019 and will expire on the date that is the later of (a)&#160;the first anniversary of the date as of which it ceases to have the right to appoint a director and (b)&#160;the date on which it holds less than 5% of the then outstanding shares of BeiGene. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Upon the Closing: </p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:5%;text-align:left;">&#160;</td>
<td style="width:3%;vertical-align:top;">&#8226;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Amgen will have the right to designate a director to serve on BeiGene&#8217;s board of directors until the earlier of (i)&#160;the date on which Amgen holds less than 10% of the then outstanding shares of BeiGene as a result of Amgen&#8217;s sale of ordinary shares or Amgen&#8217;s <span style="white-space:nowrap">non-participation</span> in future offerings and (ii)&#160;the third anniversary of the date of the expiration or termination of the Collaboration Agreement;</td> </tr> </table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:5%;text-align:left;">&#160;</td>
<td style="width:3%;vertical-align:top;">&#8226;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Amgen has agreed to vote its shares for the election of directors and certain routine corporate matters consistent with the vote of the majority of BeiGene&#8217;s board of directors and, in any matter relating to the Collaboration Agreement, in accordance with and proportional to the votes cast by other shareholders, until the later of the fifth anniversary of the Closing and the expiration of the standstill period, and has executed a proxy in furtherance thereof;</td> </tr> </table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:5%;text-align:left;">&#160;</td>
<td style="width:3%;vertical-align:top;">&#8226;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Amgen has agreed to a <span style="white-space:nowrap">lock-up</span> on sales of its shares until the earliest of (i)&#160;the fourth anniversary of the Closing, (ii)&#160;the expiration or termination of the Collaboration Agreement and (iii)&#160;a change in control of BeiGene. Following the later of (i) the expiration of the lock-up period and (ii) the expiration of the standstill period, Amgen has agreed not to sell shares representing more than 5% of the then outstanding shares of BeiGene in any rolling <span style="white-space:nowrap">12-month</span> period, subject to specified exceptions. After the expiration of the <span style="white-space:nowrap">lock-up</span> period, Amgen will have specified registration rights and will have the right to convert its shares into ADSs with reasonable cooperation from BeiGene and its depositary agent; and</td> </tr> </table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:5%;text-align:left;">&#160;</td>
<td style="width:3%;vertical-align:top;">&#8226;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">In the case that BeiGene has sold, in the event of a delay in regulatory approval for the share purchase transaction, additional ordinary shares in a <span style="white-space:nowrap">follow-on</span> public offering in an amount of up to $1&#160;billion prior to the Closing (the &#8220;<span style="text-decoration:underline;white-space:nowrap">Follow-On Offering</span>&#8221;), and Amgen has not already purchased 20.5% of the shares in such <span style="white-space:nowrap">Follow-On</span> Offering (the &#8220;<span style="text-decoration:underline">Incremental Shares</span>&#8221;), Amgen will have the opportunity to purchase the Incremental Shares.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Amgen intends to account for its interest in BeiGene under the equity method, and has certain protections under the Share Purchase Agreement to maintain its percentage interest subject to the terms thereunder. Specifically, Amgen is entitled to acquire additional shares in the market under the terms of the standstill in order to maintain its percentage interest and BeiGene has agreed that if Amgen holds no more than 20.5% of BeiGene&#8217;s outstanding shares at the time of a securities offering conducted by BeiGene, BeiGene will then use reasonable best efforts to provide Amgen with an opportunity to </p> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">participate in the offering upon the same terms and conditions as other purchasers in the offering up to the amount needed to allow Amgen to hold 20.5% of BeiGene&#8217;s outstanding shares after the offering, subject to specified exceptions, applicable law and Hong Kong stock exchange rules. Furthermore, in the event that Amgen does not have a commercially reasonable opportunity to purchase additional shares in order to maintain its percentage interest in BeiGene and, as a result, Amgen&#8217;s shares no longer qualify for equity method accounting, the <span style="white-space:nowrap">lock-up</span> on Amgen&#8217;s shares may be suspended, subject to specified conditions, and Amgen may sell down its shares until its percentage interest in BeiGene is reduced to 10%.&#160;&#160;&#160;&#160;</p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Share Purchase Agreement contains customary representations and warranties and may be terminated at any time prior to the Closing: (i)&#160;by mutual written consent of the parties; (ii)&#160;upon written notice by either party on or after June&#160;30, 2020 if the Closing has not been consummated by that date, unless such end date is extended in specified circumstances to September&#160;30, 2020 if the Closing has not been consummated by that date; (iii) by either party if certain closing conditions are not met; (iv)&#160;by either party upon the other party&#8217;s uncured material breach; or (v)&#160;upon written notice by either party if the Collaboration Agreement is terminated. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The foregoing descriptions of the terms of the Collaboration Agreement and Share Purchase Agreement are not complete and are qualified in their entirety by reference to the Collaboration Agreement and Share Purchase Agreement, copies of which Amgen intends to file as exhibits to a subsequent periodic report.</p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;7.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Regulation FD Disclosure.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">Amgen has issued a press release which is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d)&#160;&#160;&#160;&#160;Exhibits </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:3%;"></td>
<td style="width:90%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Exhibit <br />No. </p> </td>
<td style="white-space:nowrap;vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Description </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d816951dex991.htm">Press Release, dated October&#160;31, 2019</a>.</p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document). </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:45%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:3%;"></td>
<td style="width:1%;"></td>
<td style="width:44%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">AMGEN INC. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date:&#160;October&#160;31, 2019 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By:</p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Jonathan P. Graham </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Jonathan P. Graham </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Executive Vice President, General Counsel and Secretary </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d816951dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816951001.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>News Release</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Thousand&nbsp;Oaks,&nbsp;CA&nbsp;91320-1799</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1000</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">www.Amgen.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN ENTERS INTO STRATEGIC COLLABORATION WITH </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BEIGENE TO EXPAND ONCOLOGY PRESENCE IN CHINA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amgen to Acquire 20.5% Stake in BeiGene for Approximately </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$2.7 Billion in Cash </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BeiGene to Commercialize XGEVA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (denosumab), KYPROLIS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(carfilzomib) and
BLINCYTO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (blinatumomab) in China </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Companies to Collaborate on Advancing
Amgen&#146;s </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Innovative Oncology Pipeline in China </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amgen Will Continue to Commercialize its <FONT STYLE="white-space:nowrap">Non-Oncology</FONT> Product </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Portfolio in China </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amgen to Host Call for Investors Today at 2 p.m. PT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THOUSAND OAKS, Calif. (Oct. 31, 2019) &#150; Amgen (NASDAQ:AMGN) announced today that it has entered into a strategic collaboration with BeiGene that will
significantly accelerate Amgen&#146;s plans to expand its oncology presence in China, the world&#146;s second-largest pharmaceutical market. BeiGene is a research-based, oncology-focused biotechnology company with an established and highly
experienced team in China, including a <FONT STYLE="white-space:nowrap">700-person</FONT> commercial organization and a <FONT STYLE="white-space:nowrap">600-person</FONT> clinical development organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This strategic collaboration with BeiGene will enable Amgen to serve significantly more patients by expanding our presence in the world&#146;s most
populous country,&#148; said Robert A. Bradway, Amgen&#146;s chairman and chief executive officer. &#147;Cancer is a leading cause of death in China and will only become a more pressing public health issue as the Chinese population ages. With its
extensive commercial and clinical capabilities within China and a commitment to global quality standards, BeiGene is the ideal strategic collaborator as we seek to make a meaningful difference in the lives of millions of cancer patients in China and
around the world.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the collaboration: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amgen will acquire a 20.5% stake in BeiGene for approximately $2.7&nbsp;billion in cash. This represents a
purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ, a 36% premium to BeiGene&#146;s <FONT STYLE="white-space:nowrap">30-day</FONT> volume-weighted average share price as of Oct.&nbsp;30, 2019. Amgen will nominate one person to
serve on BeiGene&#146;s Board of Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the agreement, BeiGene will commercialize XGEVA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(denosumab), KYPROLIS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (carfilzomib) and BLINCYTO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (blinatumomab) in China during which time the parties will equally share profits and
losses. Two of these products will revert to Amgen, one after five years and one after seven years. Following the commercialization period BeiGene </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
will have the right to retain one product and will be entitled to receive royalties on sales in China for an additional five years on the products not retained. XGEVA was launched in China in
September of this year; KYPROLIS and BLINCYTO are both in Phase 3 trials in China. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amgen and BeiGene will collaborate to advance 20 medicines from Amgen&#146;s innovative oncology pipeline in
China and globally. BeiGene will share global research and development costs and contribute up to $1.25&nbsp;billion to advance these medicines. Amgen will pay royalties to BeiGene on the sales of these products outside of China, with the exception
of AMG 510, Amgen&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> KRAS<SUP STYLE="font-size:85%; vertical-align:top">G12C</SUP>&nbsp;inhibitor that is being studied as a potential treatment for
solid tumors. Amgen anticipates utilizing data from clinical trials conducted in China to advance the development of its oncology portfolio globally. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Of the 20 oncology medicines in development, BeiGene will assume commercial rights in China for seven years after
launch for those that receive approval in China, including AMG 510. After this time, BeiGene will retain rights to up to six of these products in China, excluding AMG 510, while rights on remaining products revert to Amgen. Amgen and BeiGene will
share profits in China equally on these products until the rights revert to Amgen, after which Amgen will pay royalties to BeiGene on sales in China for a period of five years after reversion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amgen will continue to commercialize its <FONT STYLE="white-space:nowrap">non-oncology</FONT> product portfolio
in China. Earlier this year, Amgen launched its first-ever product in China, Repatha<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (evolocumab), an LDL cholesterol-lowering treatment proven to reduce the risk of heart attacks and stroke.
Amgen expects to launch a number of other <FONT STYLE="white-space:nowrap">non-oncology</FONT> medicines in China over the next several years, including Prolia<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (denosumab), which reduces the
risk of fracture in postmenopausal women with osteoporosis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XGEVA, KYPROLIS and BLINCYTO, as well as the medicines in Amgen&#146;s oncology pipeline, will be manufactured at
Amgen&#146;s existing facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2011, Amgen has expanded its geographic presence from approximately 50 to 100 countries,
enabling the company to play a growing role in serving the rapidly increasing demand for better healthcare around the world. The pharmaceutical market in China is expected to grow briskly as access to new medicines continues to improve. With
approximately four million people diagnosed with cancer annually and 2.3&nbsp;million deaths from the disease each year, the need for new oncology treatments in China is particularly acute and the oncology market is one of the fastest-growing
segments of the overall pharmaceutical market there. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen will purchase its equity stake in BeiGene with available cash and expects to retain its
investment grade credit rating. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amgen&#146;s capital allocation priorities remain unchanged,&#148; said David W. Meline, executive
vice president and chief financial officer at Amgen. &#147;We will continue to grow our business through internal investment and business development, while providing attractive returns to our shareholders through a growing dividend and continued
share repurchases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction is expected to close in early 2020 subject to BeiGene shareholder approval, the expiration or termination of
waiting periods under all applicable antitrust laws, and satisfaction of other customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC is acting
as exclusive financial advisor, and Latham&nbsp;&amp; Watkins LLP is serving as legal advisor to Amgen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen&nbsp;will&nbsp;host a webcast&nbsp;call today&nbsp;at&nbsp;2&nbsp;p.m.&nbsp;PT. where members of Amgen&#146;s executive management team will discuss the
Company&#146;s strategic collaboration with BeiGene.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Live audio webcast of the&nbsp;investor&nbsp;call&nbsp;will be broadcast over&nbsp;the internet
simultaneously and will be available to members of the news media, investors and the general public.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The webcast, as with other selected presentations
regarding developments in Amgen&#146;s business given at certain investor and medical conferences, can be accessed on Amgen&#146;s website, <U>www.amgen.com</U>, under Investors. Information regarding presentation times, webcast availability and
webcast links are noted on Amgen&#146;s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about Amgen&#146;s products, including important safety information, please visit <U>www.xgeva.com</U>, <U>www.kyprolis.com</U>,
<U>www.blincyto.com</U>, <U>www.repatha.com</U>, and <U>www.prolia.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amgen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and
dramatically improve people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world&#146;s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of
medicines with breakaway potential.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit <U>www.amgen.com</U> and follow us on <U>www.twitter.com/amgen</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the
outcome, benefits and synergies of the BeiGene strategic collaboration, including the impact on <FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS, as </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices,
customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent periodic reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and current reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake
any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical
and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic
conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to
extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be
impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations
in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key
facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. We rely on
collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed
products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is
uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and
component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product
similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other
companies or products and to integrate the operations of companies or in support of products we have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and
availability of our systems and our data. Our stock price is volatile and may be </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our
common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: Amgen, Thousand Oaks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trish Hawkins, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-5631</FONT></FONT> (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jessica Akopyan, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">805-447-0974</FONT></FONT> (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arvind Sood,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1060</FONT></FONT> (investors) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20191031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/1/2019 1:01:46 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:amgn="http://www.amgen.com/20191031"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20191031"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20191031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20191031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20191031_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_A1.250SeniorNotesDue2022Member" name="A1.250SeniorNotesDue2022Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_A2.00SeniorNotesDue2026Member" name="A2.00SeniorNotesDue2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20191031_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/1/2019 1:01:48 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20191031.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="amgn-20191031.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A1.250SeniorNotesDue2022Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="30.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20191031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/1/2019 1:01:46 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="amgn-20191031.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="amgn-20191031.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="amgn-20191031.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A1.250SeniorNotesDue2022Member" xlink:to="amgn_A1.250SeniorNotesDue2022Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A1.250SeniorNotesDue2022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.250 Senior Notes Due 2022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A1.250SeniorNotesDue2022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.250 Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:href="amgn-20191031.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A2.00SeniorNotesDue2026Member" xlink:to="amgn_A2.00SeniorNotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 2.00 Senior Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 2.00 Senior Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20191031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/1/2019 1:01:47 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20191031.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="amgn_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A1.250SeniorNotesDue2022Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20191031.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g816951001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g816951001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 1@#L P$1  (1 0,1 ?_$ +<   ,  @,!
M       &!P4( 0($ P$  @,! 0$               4!! 8" P<0  $# P(#
M P(1!@L)      $" P0 $04&!R$Q$D%1$V$B<8&1H;$R4M*3%'05518W"!C1
M0F)RPC:"DB,S4V-SLR14%_#!HD1D)74F)Q$  0,# @('!0<% 0       0 "
M Q$$!2$2,4%1<2(R4A,589$S%#2!P4)B<B,6H;'A) ;P_]H # ,!  (1 Q$
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M765)<;6.I"TFX(/(@BDFM:%/@X$5"DFJ=\LEA-1Y#%(Q3+S<-TM)=4XI)58
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M["8M_)3W/"C1QU*/:H]B4CM43RKID1>X-"\IIFQL+G<EK-KC7^8U5.*Y"RS
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MD8?J.>]JQZZWPJMZ!+X@C\/.I_I&'ZCGO:/76^%'H$OB":WMI\VYMU'TN);
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L4(10A%"$4(7!\M""@4*%S0I10A%"$4(10A%"$4(10A%"$4(10A%"$4(7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>8
<FILENAME>0001193125-19-280582-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-19-280582-xbrl.zip
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M]']2/"6F8C0FIJ&TF3T)I=,NUKR"FY$[A[2[Q;>WNLE)I.I3@IK91EK?W*L
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MX^:&!PC9,0 I+^'T=)* ^[&!=TQZGNF<(<"\!QRDK*LNFMF\,-Y@=K4"]/
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M^OX#"'[P@/[O$/B2_Z<2_PU02P$"% ,4    " "EB%]/FK*]_3L$  #U$0
M$0              @ $     86UG;BTR,#$Y,3 S,2YX<V102P$"% ,4
M" "EB%]/^%,H]-\%   8-@  %0              @ %J!   86UG;BTR,#$Y
M,3 S,5]D968N>&UL4$L! A0#%     @ I8A?3Q<!D*[T!P  K5D  !4
M         ( !? H  &%M9VXM,C Q.3$P,S%?;&%B+GAM;%!+ 0(4 Q0    (
M *6(7T^!J,>TF04  .,Y   5              "  :,2  !A;6=N+3(P,3DQ
M,#,Q7W!R92YX;6Q02P$"% ,4    " "EB%]/6Z"<N!<A  #%TP  #@
M        @ %O&   9#@Q-CDU,60X:RYH=&U02P$"% ,4    " "EB%]/B D!
M*&,:  !;8@  $0              @ &R.0  9#@Q-CDU,61E>#DY,2YH=&U0
52P4&      8 !@"# 0  1%0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\KL*^LV[G_K'Q15#5\.LNU!=02P,$%     @ I8A?3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MXFC8_7=S,J67=ROQ'FM;MOW?:'ULG:V&+GXI5?Y^N19U?SU?GF2CH0P7T%!
MUP)-_5XN1OW*/^<N7\X;>XZ:R\L_Y%W&ZI'\NUEWD_VKZ)_YQ;=^]K1,Y\FI
M:S,HGBX*NE&HJR+QO:\&! VH+]<WY83+-2S7?7EV4ZZ#]7%%A@TR:)"Q\E%@
MP!5C;#""!B-6/@D,N&**#<;08,S*9X$!5Z@4.TR@PX37J\ "2(2<I]!BRNO#
MH(%$2'H&+6:\/HP:2(2L58IQ2GF',&ZD$0)7 K2*=P@S!QH20E>87$6\0Q@[
MT@BY*PRXXOQ2F#S2"-$K3+GB$%,8/M)(Z6/4%2>96/I (Z6/>5<<9V+I<XV6
MTL?,*TZT9NESC?3",/6*,ZTI-.$:R01SKSC5FGW"N$8P(0P^<:AU%I@ C62"
MN2?.M X_Q4 CF0@_V!QI+77 2).^]S>?,*W$2=0A1T@C<$285N(DZI CH,D$
MC@C32IS$+.0(::0WAFDE3F*FA0X819K>'1K&C !F+#2NR80O<HTYTX"S,#2@
MR4:""P9-<XA8:$@C<*(Q:9J3EDV$#L)_QW>3IC%I^@[2@"832-.8-'T':4"3
MS0073)J^@S2D"4-+;LY.W=GT1][LBKJ-5M;Y8UA_6-I:ZXSOES[X5>_]<?@Z
M*,W6=;<3?]]<SH27@;.'X;R;7 _=R_]02P,$%     @ I8A?3\"#7EN3 @
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M_VTP",\.&C'._MAL]3T[MU9.[Z5HM8*XEM\63&XL6&1\K4,ZX\2KYPLWI?(
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MA@8MU&\\(##.(50;+^*1=*:W=Y-[#KO7^H&Q=_OJ5-*/&N/'+7\ 4$L#!!0
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MK_>PGPG;83UVX=\@J6$Z[];_:'29RZ!=_,W(1TKM05\-_\GR"U!+ 0(4 Q0
M   ( *6(7T\?(\\#P    !,"   +              "  0    !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( *6(7T\GZ(<.@@   +$    0              "
M >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ I8A?3];A=!WO
M*P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ I8A?3YE<G",0!@  G"<  !,              ( !MP(  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "EB%]/&G9770H#  " #P  &
M            @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ I8A?3\"#7EN3 @  -@<  !0              ( !. P  'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ I8A?3[JA.8K7 0  ,@8   T
M             ( !_0X  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "EB%]/
M%FTC?T,!   \ @  #P              @ '_$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ I8A?3__ )@B]    A0(  !H              ( !;Q(
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ I8A?3PN/
MV ,A 0  5P0  !,              ( !9!,  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      H "@"  @  MA0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6621712368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMGEN INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member', window );">A 1.250 Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.250% Senior Notes Due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">A 2.00 Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.000% Senior Notes Due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d816951d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 4,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20191031_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d816951d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20191031_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20191031_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20191031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 2,
   "memberStandard": 1,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20191031",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d816951d8k.htm",
      "contextRef": "duration_2019-10-31_to_2019-10-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d816951d8k.htm",
      "contextRef": "duration_2019-10-31_to_2019-10-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "amgn_A1.250SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 1.250 Senior Notes Due 2022 [Member]",
        "terseLabel": "A 1.250 Senior Notes Due 2022 [Member]"
       }
      }
     },
     "localname": "A1.250SeniorNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20191031",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 2.00 Senior Notes Due 2026 [Member]",
        "terseLabel": "A 2.00 Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20191031",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.amgen.com/20191031",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.amgen.com/20191031",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d816951d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20191031"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20191031.xsd" xlink:type="simple"/>
    <context id="duration_2019-10-31_to_2019-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2019-10-31_to_2019-10-31"
      id="Hidden_dei_EntityRegistrantName">AMGEN INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2019-10-31_to_2019-10-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2019-10-31_to_2019-10-31"
      id="Hidden_dei_EntityCentralIndexKey">0000318154</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2019-10-31_to_2019-10-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2019-10-31_to_2019-10-31">2019-10-31</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2019-10-31_to_2019-10-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2019-10-31_to_2019-10-31">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2019-10-31_to_2019-10-31">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2019-10-31_to_2019-10-31">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2019-10-31_to_2019-10-31">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2019-10-31_to_2019-10-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2019-10-31_to_2019-10-31">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2019-10-31_to_2019-10-31">(805)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2019-10-31_to_2019-10-31">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2019-10-31_to_2019-10-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2019-10-31_to_2019-10-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2019-10-31_to_2019-10-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2019-10-31_to_2019-10-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">1.250% Senior Notes Due 2022</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">AMGN22</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-10-31_to_2019-10-31_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2019-10-31_to_2019-10-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d816951d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20191031/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d816951d8k.htm">d816951d8k.htm</File>
    <File>amgn-20191031.xsd</File>
    <File>amgn-20191031_def.xml</File>
    <File>amgn-20191031_lab.xml</File>
    <File>amgn-20191031_pre.xml</File>
    <File>d816951dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
